JP7882832B6 - ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法 - Google Patents
ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法Info
- Publication number
- JP7882832B6 JP7882832B6 JP2023508084A JP2023508084A JP7882832B6 JP 7882832 B6 JP7882832 B6 JP 7882832B6 JP 2023508084 A JP2023508084 A JP 2023508084A JP 2023508084 A JP2023508084 A JP 2023508084A JP 7882832 B6 JP7882832 B6 JP 7882832B6
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- ketotifen
- nsaid
- combination pharmaceutical
- indomethacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062138P | 2020-08-06 | 2020-08-06 | |
| US63/062,138 | 2020-08-06 | ||
| PCT/US2021/044897 WO2022032069A1 (en) | 2020-08-06 | 2021-08-06 | Compositions and methods for treating or preventing disease associated with beta coronavirus infection |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023537369A JP2023537369A (ja) | 2023-08-31 |
| JP2023537369A5 JP2023537369A5 (cg-RX-API-DMAC7.html) | 2024-08-14 |
| JP7882832B2 JP7882832B2 (ja) | 2026-06-30 |
| JP7882832B6 true JP7882832B6 (ja) | 2026-07-31 |
Family
ID=80117684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023508084A Active JP7882832B6 (ja) | 2020-08-06 | 2021-08-06 | ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240033259A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192457B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7882832B6 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048517A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322662A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021321535A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188387A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3069166T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300406A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001570A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046201A1 (en) | 2017-08-30 | 2019-03-07 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION |
| CN116178373B (zh) * | 2022-12-06 | 2024-06-18 | 南方科技大学 | 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180360811A1 (en) | 2017-06-16 | 2018-12-20 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections |
| US20190060297A1 (en) | 2017-08-30 | 2019-02-28 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations |
-
2021
- 2021-08-06 WO PCT/US2021/044897 patent/WO2022032069A1/en not_active Ceased
- 2021-08-06 EP EP21853813.0A patent/EP4192457B1/en active Active
- 2021-08-06 ES ES21853813T patent/ES3069166T3/es active Active
- 2021-08-06 US US18/019,959 patent/US20240033259A1/en active Pending
- 2021-08-06 MX MX2023001570A patent/MX2023001570A/es unknown
- 2021-08-06 JP JP2023508084A patent/JP7882832B6/ja active Active
- 2021-08-06 KR KR1020237006880A patent/KR20230048517A/ko active Pending
- 2021-08-06 IL IL300406A patent/IL300406A/en unknown
- 2021-08-06 CA CA3188387A patent/CA3188387A1/en active Pending
- 2021-08-06 AU AU2021321535A patent/AU2021321535A1/en active Pending
- 2021-08-06 CN CN202180068018.3A patent/CN116322662A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180360811A1 (en) | 2017-06-16 | 2018-12-20 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections |
| US20190060297A1 (en) | 2017-08-30 | 2019-02-28 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations |
Non-Patent Citations (4)
| Title |
|---|
| GOMENI, Roberto et al.,"Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2",Journal of Pharmacokinetics and Pharmacodynamics,2020年05月20日,Vol. 47,No. 3,p. 189-198,DOI: 10.1007/s10928-020-09690-4 |
| JIMNEZ-ALBERTO, Alicia et al.,"Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors",Computational Biology and Chemistry,2020年06月25日,Vol. 88,p. 107325,DOI: 10.1016/j.compbiolchem.2020.107325 |
| MARINELLA, Mark A.,"Indomethacin and resveratrol as potential treatment adjuncts for SARS‐CoV‐2/COVID‐19",International Journal of Clinical Practice,2020年06月12日,Vol. 74,No. 9,DOI: 10.1111/ijcp.13535 |
| NAPOLI, Pietro Emanuele et al.,"A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era",Journal of Clinical Medicine,2020年07月30日,Vol. 9,No. 8,p. 2441,DOI: org/10.3390/jcm9082441 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001570A (es) | 2023-05-03 |
| JP7882832B2 (ja) | 2026-06-30 |
| US20240033259A1 (en) | 2024-02-01 |
| CA3188387A1 (en) | 2022-02-10 |
| EP4192457A4 (en) | 2024-09-18 |
| IL300406A (en) | 2023-04-01 |
| EP4192457C0 (en) | 2026-03-25 |
| JP2023537369A (ja) | 2023-08-31 |
| CN116322662A (zh) | 2023-06-23 |
| WO2022032069A1 (en) | 2022-02-10 |
| EP4192457A1 (en) | 2023-06-14 |
| KR20230048517A (ko) | 2023-04-11 |
| AU2021321535A1 (en) | 2023-03-23 |
| ES3069166T3 (en) | 2026-06-04 |
| EP4192457B1 (en) | 2026-03-25 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240805 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240805 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250930 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260519 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260618 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7882832 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |